Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma.
Bewicke-Copley F., Korfi K., Araf S., Hodkinson B., Kumar E., Cummin T., Ashton-Key M., Barrans SL., van Hoppe SJ., Burton C., Elshiekh M., Rule S., Crosbie N., Clear AJ., Calaminici M., Runge HFP., Hills RK., Scott DW., Rimsza LM., Menon G., Sha C., Davies J., Nagano A., Davies AJ., Painter D., Smith A., Gribben JG., Naresh KN., Westhead DR., Okosun J., Steele AJ., Hodson DJ., Balasubramanian S., Johnson PWM., Wang J., Fitzgibbon J.
Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but falling short of providing a consistent relapse-specific genetic signature. In our study, we have focussed attention on the changes in gene expression profile accompanying DLBCL relapse using archival paired diagnostic/relapse specimens from 38 de novo DLBCL patients. Cell of origin remained stable from diagnosis to relapse in 84% of patients, with only a single patient showing COO switching from ABC to GCB. Analysis of the transcriptomic changes that occur following relapse suggest ABC and GCB relapses are mediated via different mechanisms. We developed a 30-gene discriminator for ABC-DLBCLs derived from relapse-associated genes, that defined clinically distinct high and low risk subgroups in ABC-DLBCLs at diagnosis in datasets comprising both population-based and clinical trial cohorts. This signature also identified a population of <60-year-old patients with superior PFS and OS treated with Ibrutinib-R-CHOP as part of the PHOENIX trial. Altogether this new signature adds to the existing toolkit of putative genetic predictors now available in DLBCL that can be readily assessed as part of prospective clinical trials.